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ORIGINAL ARTICLE
Background/Aims: As bacterial resistance to antimicrobial agents has grown due to the increasing use of
antimicrobial agents, we sought to evaluate the suitability of ceftriaxone usage (representative of third generation
cephalosporins) at 10 university hospitals in Korea.
Methods: We prospectively evaluated the appropriateness of antibiotic usage in 400 adult patients who received
ceftriaxone between February 1, 2006 and June 30, 2006. Drug utilization evaluation (DUE) methods were based
on standards set forth by the American Society of Hospital Pharmacists. The DUE criteria used in this study were
modified to be more suitable in our hospital setting: justification of drug use, critical and process indications,
complications, and outcome measures.
Results: The average patient age was 64.4 years. The utilization of ceftriaxone was appropriate in 262 cases
(65.5%) for the justification of use, while inappropriate use was observed in 138 cases (34.5%). Common reasons
for inappropriate use of ceftriaxone included continued empiric use for presumed infections, prophylactic
perioperative injection, and empiric therapy for fever. Most of the critical indications showed a high rate of suitability
(66.5-98.5%). Complications occurred in 37 cases (9.3%).  With respect to outcome measures, clinical responses
were observed in 60.7% of cases, while only 15.7% of cases showed evidence of infection eradication via negative
cultures.
Conclusions: Appropriate use (65.5%) of ceftriaxone was higher than inappropriate use (34.5%) at university hospitals
in Korea. Inappropriate utilization, however, including continued empiric use for presumed infections and prophylactic
perioperative injection remained high. Intensification of educational programs and antibiotic control systems for
ceftriaxone is needed to improve the suitability of antimicrobial use. (Korean J Intern Med 2009;24:374-380)
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INTRODUCTION
Bacterial resistance to antimicrobial agents due to the
increasing use of antimicrobial agents has become a
worldwide concern. Over the past several decades, the
increased prevalence of known resistant organisms and
the emergence of newly resistant organisms such as
penicillin-resistant pneumococci, methicillin-resistant
Staphyloccus aureus, vancomycin-resistant enterococci,
extended-spectrum beta-lactamase-producing Escherichia
coli, Klebsiella pneumoniae, and imipenem-resistant
gram-negative bacilli, have resulted in delays in effective
therapy and the length of hospitalization, and have led to
increased costs for patients [1]. Compared to infectionsLee H, et al. Drug utilization evaluation of ceftriaxone     375
Table 1. Criteria elements for the drug utilization evaluation of ceftriaxone
No. Elements Exceptions
Justification of use 
1 Culture and sensitivity (C&S) documented serious gram negative Organism need not be resistant to ampicillin, and trimethoprim-
pulmonary infection (not pseudomonas) sensitive to ceftriaxone sulfamethoxazole if patient has documented allergy to beta-lactam
antibiotics or sulfonamides
2 C&S documented acute or chronic gram negative osteomyelitis None
Or
3 C&S documented meningitis due to enteric bacteria or  None
Hemophilus influenzae
Or
4 C&S documented gonorrhea, gonococcal infection None
Or
5 C&S documented pelvic inflammatory disease None
Or
6 C&S documented chancroid None
Or
7 C&S documented gram negative bacteremia (not pseudomonas) None
Or
8 C&S documented serious infection due to multidrug resistant gram  None
negative microorganism
Or
9 Empiric treatment of suspected gram negative bacteremia/septicemia None
in non-neutropenic patient or severe pneumonia
Or
10 Empiric treatment of suspected gram-negative non-pseudomonal  None
meningitis
Or
11 Empiric treatment of sexually acquired epididymitis None
Critical (process) indicators
12 Appropriate C&S obtained within 48 hr  Ceftriaxone ordered in response to positive culture
before initial ceftriaxone dose
13 Complete blood count (CBC) with differential obtained within  None
48 hr before initial ceftriaxone dose
14 Serum creatinine (SCr) concentration or urinary creatinine clearance If severe hepatic and renal impairment, total daily dose lower than
(CrCl) obtained if severe hepatic and renal impairment occurs or equal to 2 g
15 Liver function tests [total serum bilirubin, alkaline phosphatase  None
(ALP), aspartate aminotransferase (AST), 
and alanine aminotransferase (ALT)] obtained within 7 days before
initial ceftriaxone dose
16 Previous hypersensitivity reaction to beta-lactam antibiotics NOT  None
noted in patient’s chart
17 Appropriate ceftriaxone dosage; None
(a) uncomplicated gonorrhea/gonococcal infection: 
250 mg IM single dose
(b) disseminated gonorrhea/gonococcal infection:
1 g IV q 24 hr for 7 days
(c) pelvic inflammatory disease: 250 mg IM as a single dose
followed by doxycycline
(d) sexually acquired epididymitis: 250 mg IM as a single dose
followed by doxycycline 
(e) chancroid : 250 mg IM as a single dose
(f) moderate infection: 1-2 g IV/IM q 24 hr
(g) severe infection: 1 g IV/IM q 12 hr or 2g IV/IM q 24 hr376 The Korean Journal of Internal Medicine Vol. 24, No. 4, December 2009
No. Elements Exceptions
18 Vital signs monitored at least three times daily  None
(i.e., once each nursing shift) until patient becomes afebrile and at
least one daily thereafter during ceftriaxone therapy None
19 White blood cell (WBC) count obtained at least once weekly during None
ceftriaxone therapy
20 SCr or urinary CrCl obtained at least once weekly during  None
ceftriaxone therapy
21 Appropriate treatment duration: 7-14 days None
Complications
22 Anaphylaxis: breathing difficulty, wheezing, laryngeal edema,  Discontinue ceftriaxone 
flushing, tarchycardia, and/or hypotension Treat symptomatically with epinephrine or antihistamine with or with
or without supportive care, e.g., fluids, cardiopulmonary
resuscitation, and assisted ventilation
Use alternative anti-infective therapy
23 Cutaneous reactions: urticaria, angioedema, maculopapular  Identify other drug and nondrug causes
eruptions, pruritus, erythema multiforme, and/or Stevens-Johnson  If mild reaction, treat symptomatically with antihistamine or
syndrome corticosteroid; pretreat with antihistamine or corticosteroid for
subsequent doses
If severe reaction, discontinue ceftriaxone; treat symptomatically
with epinephrine or antihistamine with or without supportive care,
including cardiopulmonary resuscitation and assisted ventilation;
use alternative anti-infective therapy
24 Superinfection; overgrowth of another organism (e.g., Enterococcus, Discontinue ceftriaxone and treat primary infection with alternative
Candida, Pseudomonas, or Acinetobacter species) antimicrobial if possible Begin appropriate anti-infective therapy for
superinfection
25 Gastrointestinal effects: nausea, dyspepsia, diarrhea, constipation,  Identify other drug and nondrug causes
vomiting, abdominal pain or discomfort, oral ulceration, dysphagia, Provide symptomatic care and supportive therapy If mild reaction, 
intestinal perforation, ileus, dry mouth, and/or gastrointestinal bleeding decrease dosage If severe reaction, discontinue ceftriaxone and
switch to alternative anti-infective therapy
26 Bad taste Identify other drug and nondrug causes
If mild reaction, decrease dosage
If severe reaction, discontinue ceftriaxone and switch to alternative
anti-infective therapy
27 Antimicrobial-associated pseudomembranous colitis (AAPMS)  Identify and discontinue causative agent and use alternative
characterized by at least two of the following: anti-infective therapy if possible
(a) fever, diarrhea, abdominal pain, or ileus Replace fluid and electrolyte losses with IV or oral therapy if nothing-
(b) proctoscopy or colonoscopy revealing yellow-white exudative by-mouth order is discontinued
plaques or pseudomembranes  Initiate therapy per severity of condition: IV metronidazole for patient
(c) biopsy showing histologic changes consistent with AAPMS with nothing-by-mouth orders ; or oral vancomycin, metronidazole, or
(d) fecal leukocytes bacitracin, each with or without anion-exchange resin, if nothing-by-
(e) positive culture for Clostridium difficile with or without positive   mouth order is discontinued 22-24 hr
C. difficile tox
28 Neurologic effects: peripheral neuropathy manifested as  Identify other drug and nondrug causes
paresthesia, numbness or ataxia, and/or incoordination or convulsion Discontinue ceftriaxone and treat symptomatically; use alternative
anti-infective therapy
29 Central nervous system effects: drowsiness, fatigue, malaise,  Identify other drug and nondrug causes
lethargy, psychosis, depression, mania, phobia, confusion,  If mild reaction, treat symptomatically
hallucinations, dizziness, lightheadedness, anxiety, tremor,  If severe or intolerable reaction, discontinue ceftriaxone and treat 
and/or insomnia symptomatically; use alternative anti-infective therapy
30 Hepatotoxicity as measured by liver function tests   (e.g., right upper quadrant pain or tenderness, jaundice, nausea,
(at least two times upper limit of normal) for one or  and vomiting) Identify other drug and nondrug causes
more of the following: ALT, AST, ALP, lactate dehydrogenase,  Discontinue ceftriaxone and switch to alternative anti-infective therapy
and bilirubin; or clinical symptoms of liver disease (e.g., right upper  Monitor liver enzymes at least twice weekly until values return to
quadrant pain or tenderness, jaundice, nausea, and vomiting) normal or to patient’s baselineLee H, et al. Drug utilization evaluation of ceftriaxone     377
caused by susceptible pathogens, those caused by resistant
pathogens are associated with higher rates of morbidity
and mortality [2,3]. Furthermore, antimicrobial drug
resistance has been projected to add between $100
million and $30 billion annually to health-care costs [4].
During the past several years, the problem of antibiotic
resistance has noticeably worsened in Korea [5]. With
gradual increases in expensive antimicrobial agents,
the cost of antimicrobial agents relative to total medical
insurance expenses has reached 33.1% [6]. When
considering that misuse of antimicrobial agents is the
most important cause of antibiotic resistance, the logical
first step is to evaluate the suitability of antibiotic usage. 
Only one usage analysis of cephalosporins and amino-
glycosides for surgical prophylaxis has been conducted at
a university hospital in Korea, and most reports examining
the appropriateness of antibiotic use have been individual
studies [7-12]. Antibiotic use evaluations are a basic
measure for evaluating the appropriate usage of antimi-
crobial agents; however, data gathered from individual
hospitals have limited benefits for policy-making. For this
reason, we examined antibiotic use status and evaluated
the appropriateness of the antibiotic usage in 10 university
hospitals in Korea. Specifically, in the present study, we
evaluated the use of a specific antibiotic (ceftriaxone, a
representative of third-generation cephalosporin) and
attempted to compile basic data outlining the appropriate
use of antibiotics.
No. Elements Exceptions
31 Bleeding disturbances: thrombocytopenia  Identify other drug and discontinue ceftriaxone 
(platelet count < 70,000/mm
3) or  Use alternative anti-infective therapy
Thrombocytosis (platelet count > 400,000/mm
3) Provide supportive care and symptomatic therapy; monitor PT,
activated partial thromboplastin time, and platelet count at least
twice weekly
32 Nonbleeding-related hematologic effects: leukopenia  Identify other drug and nondrug causes
(leukocyte count < 500/mm
3), eosinophilia Discontinue ceftriaxone.
(absolute eosinophil count > 500/mm
3), or pancytopenia Use alternative anti-infective therapy
Provide supportive care and symptomatic therapy; monitor CBC
with differential daily
33 Local effects of IV therapy: phlebitis, burning, pain and inflammation,  Identify other drug and nondrug causes
erythema, pruritus, paresthesia, and/or swelling If mild reaction, treat symptomatically; consider alternative IV site in
a larger vein and increase drug dilution to 1 mg/mL
If severe reaction, discontinue infusion and remove IV catheter; use
alternative anti-infective therapy
Outcome measures
34 Eradication of infection as evidenced by negative (sterile) cultures  New organism or another infection identified, clinical cure determined
72 hours after discontinuation of  ceftriaxone by absence of erythema and tenderness at affected site
Patient discharged and unavailable for follow up patient expired
Patient discharged before therapy completed
Or
35 Fever reduction (decrease of at least 1˚Cfrom peak temperature)  Fever not present initially
within 3 days of initial ceftriaxone dose Another cause of elevated temperature known or suspected new
source of infection known or suspected
Patient expired
Or
36 WBC count within normal limits (3.7-9.4 × 10
9/mm
3) WBC count not elevated prior to therapy
Patient neutropenic prior to therapy
Another cause of elevated WBC count known or suspected
Patient expired
Or
37 Clinical improvement noted in progress New organism or another infection suspected or identified
Patient discharged before therapy completed and unavailable for
follow-up
Patient expired378 The Korean Journal of Internal Medicine Vol. 24, No. 4, December 2009
METHODS
The criteria used for antibiotic selection included the
following: antibiotics with a risk of abuse, those that were
being used in high amounts in Korean hospitals, antibiotics
that were likely causing resistance due to increased usage,
and those that were not being controlled by an antibiotic
prescribing restriction system. Ceftriaxone, a broad-
spectrum parenteral cephalosporin, was selected as repre-
sentative of unrestricted antibiotics. A drug utilization
evaluation (DUE) was conducted to determine whether
ceftriaxone was being used appropriately based on the
“Criteria for Drug Use Evaluation” of the American
Society of Hospital Pharmacists [13]. The criteria for DUE
used in this study were modified based on their suitability
in the Korean hospital setting: justification of drug use,
critical and process indications, complications, and outcome
measures. A DUE was performed prospectively by reviewing
medical records for a total of 400 patients (10 hospitals
with 40 patients each) who received ceftriaxone during
hospitalization between February 1, 2006 and June 30,
2006, and these data were used in this study. Medical
records were examined for the diagnosis, the reason for
initiating and discontinuing therapy, gender, dose,
frequency of administration, culture and sensitivity (C&S)
results, renal function, and duration of antibiotic therapy.
All medical records were examined for compliance to the
clinical indicators listed above. 
Indications for which ceftriaxone was deemed either
acceptable or unacceptable are shown in Table 1. Any
patients for whom therapy was deemed unacceptable
were reviewed with criteria established at the onset of
the DUE. Enrolled hospitals were Dong-A University
Hospital, Kangbuk Samsung Hospital, Samsung Medical
Center, Chungbuk National University Hospital, Chonnam
National University Hospital, Chungnam National
University Hospital, Seoul Veterans Hospital, Kyungpook
National University Hospital, Konkuk University Hospital,
and Inje University Paik Hospital.
RESULTS
In total, 400 patients (247 men, 153 women) with a
mean age of 64.4 years (range, 3 to 93; 95% CI, 32.4 to
96.4) were reviewed, with 10 cases at each of the 10
institutions. Most cases involved the department of
internal medicine (58%); the remainders were in
neurosurgery (12%), surgery (7.5%), orthopedic surgery
(3.7%), thoracic surgery (3.7%), urology (2.7%),
otolaryngology (2%), neurology (2%), and others (4.3%).
Ceftriaxone dosing regimens are presented in Table 2. In
340 cases (85%), ceftriaxone was dosed as 2 g/day (range,
1 to 4). The mean duration of ceftriaxone use was 10.3
days (range, 1 to 61). 
Justification of ceftriaxone use
The use of ceftriaxone was appropriate in 262 cases
(65.5%), and inappropriate in 138 cases (34.5%; Fig. 1).
The causes of inappropriate ceftriaxone use included
routine perioperative prophylaxis (50%), inappropriate
empirical therapy (>5 days) for presumed infections
(34.8%), and systemic prophylaxis for infection or
Table 2. Distribution of ceftriaxone daily dosage
Daily dosage (g/day)
1.0 1.5-2.0 2.0 2.0-2.5 3.0 4.0 Total
9 (2.2%) 2 (0.5%) 340 (85.3%) 1 (0.3%) 8 (2.0%) 40 (10.0%) 400 (100%)
Table 3. Causes of inappropriate ceftriaxone use
Cause Values
(n=138)
Routine perioperative prophylaxis 69 (50)
Inappropriate empiric therapy (>5 days) for  48 (34.8)
presumed infections
Systemic prophylaxis for infection or colonization 21 (15.2)
Values are number (%).
Figure 1. Justification of the use of ceftriaxone. Lee H, et al. Drug utilization evaluation of ceftriaxone     379
colonization (15.2%, Table 3). 
Critical (process) indicators
Most of the critical and process indications showed
high rates of appropriateness (84.2-98.5%), excluding
inappropriate C&S tests prior to the initial ceftriaxone dose
(33.5%) and inappropriate duration of therapy (42.8%,
Table 4).
Complications
Hepatotoxicity occurred in 16 cases (43.2%), gastroin-
testinal trouble in 12 cases (32.4%), cutaneous reaction in
6 cases (16.2%), bleeding disturbances in 2 cases (5.5%),
and peripheral neuropathy in 1 case (2.7%, Table 5). Each
case was managed appropriately.
Outcome measures
Clinical improvement was noted in 243 patients
(60.7%), while documentation of microbiological eradi-
cation evidenced by negative cultures 72 hours after
discontinuation of ceftriaxone was inappropriate in 337
patients (84.3%). 
DISCUSSION
The goal of antibiotic therapy is to achieve the best
possible clinical outcomes while consuming the least
amount of hospital resources. Health-care systems are
under intense pressure to increase the quality of care and
at the same time reduce costs. Pressure to reduce the cost
of antimicrobial therapy is especially intense because
these drugs may account for a large portion of a hospital’s
pharmacy budget. According to previous investigations
on antibiotic use, antibiotics might account for 33.1% of
the medical insurance budget in Korea, and 20-50% of
these cases are suspected to have been abuse [6]. In many
cases, antibiotics were prescribed for prophylaxis rather
than for treatment [6,7]. Antibiotic abuse such as this in
the community and hospitals fuels the crisis of antibiotic
resistance, which ultimately results in virtually all pathogenic
bacteria becoming resistant to older antibiotics. During
the past several years, the problem of antibiotic resistance
has noticeably worsened in Korea [5].
We performed a DUE for a specific antibiotic and
attempted to gather basic data to examine the appropriate
use of antibiotics. Furthermore, we sought to prevent
antibiotic misuse and reduce unnecessary medical costs.
The one limitation of previous studies for DUE is that most
were retrospective and focused on a specific department.
To overcome this problem, we prospectively evaluated the
appropriate use of ceftriaxone usage (representative of
thirdgeneration cephalosporins) at 10 university hospitals
in Korea. Ceftriaxone is major drug that is used in the
treatment of many important infections due to its high
antibacterial potency, wide spectrum of activity, and low
potential for toxicity. Its superior activity against
Enterobacteriaceae, however, is being challenged by the
Table 4. Ceftriaxone drug utilization evaluation: critical (process) indicators
Criteria Accepted level Unaccepted level
Appropriate cultures and sensitivities obtained within 48 hr before initial ceftriaxone dose 266 (66.5) 134 (33.5)
Complete blood count with differential obtained within 48 hr before initial ceftriaxone dose 371 (92.7) 29 (7.3)
Liver function test obtained within 7 days before initial ceftriaxone dose 382 (95.5) 18 (4.5)
Previous hypersensitivity reaction to beta-lactam antibiotics NOT noted in patient’s chart 394 (98.5) 6 (1.5)
Appropriate ceftriaxone dosage 337 (84.2) 63 (15.8)
White blood cell count obtained at least 1/wk during therapy 379 (94.7) 21 (5.3)
Vital signs monitored at least three times daily 386 (96.5) 14 (3.5)
Serum creatinine (sCr) monitored at least 2/wk during therapy if baseline sCr within normal limit 376 (94) 24 (6)
Duration of therapy 229 (57.2) 171 (42.8)
Values are frequency (%).
Table 5. Ceftriaxone drug utilization evaluation:
complications
Complication Value
(n=37) 
Hepatotoxicity 16 (43.2)
GI trouble 12 (32.4)
Cutaneous reaction (e.g., skin rash) 6 (16.2)
Bleeding disturbance 2 (5.5)
Peripheral neuropathy 1 (2.7)
Values are number (%).380 The Korean Journal of Internal Medicine Vol. 24, No. 4, December 2009
increasing frequency of beta-lactamase-mediated
resistance. Kim et al. [8] reported that 47% of cases met
the criteria for justified use in a retrospective study at a
university hospital in 1999. In contrast, our study showed
that the appropriate use of ceftriaxone was relatively
higher (65.5%) as compared to other studies. This
difference may be attributable to the fact that the
justification of use criteria were stricter and our study
allowed more acceptable cases for empirical therapy.
Although the appropriateness (65.5%) of ceftriaxone
usage was higher than inappropriateness (34.5%) in
tertiary care hospitals in Korea, unsuitable utilization such
as continued empiric use for presumed infections and
prophylactic perioperative injection remained high.
Furthermore, appropriate selection of an antibiotic
according to C&S was relatively low. Of the critical indi-
cations, a lack of C&S prior to initial ceftriaxone dose and
an inappropriate duration of therapy were most common.
Others showed quite high rates of appropriateness (84.2-
98.5%, Table 4). Ceftriaxone is considered to be low in
side effects. Among the complications, hepatotoxicity (16
cases, 4%) and GI difficulties (12 cases, 3%) were most
common (Table 5). Each case was managed appropriately.
Outcome analyses showed a relatively high clinical
improvement rate of 60.7%, while microbiological
documentation by follow-up culture was poor (84.3%).
These results show that ceftriaxone, when used
empirically, should be reevaluated within 72 hours of
initiating therapy and when C&S data are reported.
Therapy should be discontinued if the C&S report
demonstrates that the organisms are sensitive to equally
efficacious, less costly antibiotics. According to data
generated by this DUE, a combination of physician
education programs and feedback control systems
directed toward rational ceftriaxone use is suggested
for proper medical treatment.
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